175 related articles for article (PubMed ID: 23648467)
1. Involved-field radiation therapy for locoregionally recurrent ovarian cancer.
Brown AP; Jhingran A; Klopp AH; Schmeler KM; Ramirez PT; Eifel PJ
Gynecol Oncol; 2013 Aug; 130(2):300-5. PubMed ID: 23648467
[TBL] [Abstract][Full Text] [Related]
2. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
Chang JS; Kim SW; Kim YJ; Kim JY; Park SY; Kim JH; Jang TK; Kim YB
Gynecol Oncol; 2018 Oct; 151(1):39-45. PubMed ID: 30146110
[TBL] [Abstract][Full Text] [Related]
3. Involved-field radiation therapy for selected cases of recurrent ovarian cancer.
Kim N; Chang JS; Kim SW; Kim GM; Lee JY; Kim YB
J Gynecol Oncol; 2019 Sep; 30(5):e67. PubMed ID: 31328453
[TBL] [Abstract][Full Text] [Related]
4. Radiation therapy for chemotherapy-resistant recurrent epithelial ovarian cancer.
Machida S; Takei Y; Yoshida C; Takahashi Y; Koyanagi T; Sato N; Taneichi A; Saga Y; Fujiwara H; Suzuki M
Oncology; 2014; 86(4):232-8. PubMed ID: 24853194
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer.
Albuquerque KV; Singla R; Potkul RK; Smith DM; Creech S; Lo S; Emami B
Gynecol Oncol; 2005 Mar; 96(3):701-4. PubMed ID: 15721414
[TBL] [Abstract][Full Text] [Related]
6. Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer.
Albuquerque K; Patel M; Liotta M; Harkenrider M; Guo R; Small W; Ronald P
Int J Gynecol Cancer; 2016 May; 26(4):655-60. PubMed ID: 26825832
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Jansaka N; Suprasert P
Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of long-term survivors of recurrent epithelial ovarian cancer.
Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Sakamoto K; Takizawa K; Takeshima N
Int J Clin Oncol; 2015 Feb; 20(1):143-9. PubMed ID: 24664306
[TBL] [Abstract][Full Text] [Related]
10. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
[TBL] [Abstract][Full Text] [Related]
11. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract][Full Text] [Related]
12. Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.
Gao Y; Liu Z; Chen X; Luo W; Zhang L; Wang J
BMC Cancer; 2011 Oct; 11():439. PubMed ID: 21989202
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
14. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
15. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
16. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
[TBL] [Abstract][Full Text] [Related]
18. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Selle F; Sevin E; Ray-Coquard I; Mari V; Berton-Rigaud D; Favier L; Fabbro M; Lesoin A; Lortholary A; Pujade-Lauraine E
Ann Oncol; 2014 Nov; 25(11):2191-2196. PubMed ID: 25210017
[TBL] [Abstract][Full Text] [Related]
20. Surgical cytoreduction for recurrent epithelial ovarian cancer.
Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]